טוען...
Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus
IMPORTANCE: Cutaneous lupus erythematosus (CLE) can be severe and treatment resistant. B-cell depletion therapy (BCDT) with rituximab is well recognized in organ involvement in systemic lupus erythematosus (SLE), but its efficacy in cutaneous manifestations is less well established. OBJECTIVE: To ev...
שמור ב:
| הוצא לאור ב: | JAMA Dermatol |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Medical Association
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6583321/ https://ncbi.nlm.nih.gov/pubmed/30383114 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2018.3793 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|